The treatment of staphylococcal endocarditis

Area of Science:

• Infectious Diseases
• Cardiology
• Microbiology

Background:

• Staphylococcal endocarditis involves Staphylococcus aureus and Staphylococcus epidermidis infecting native or prosthetic heart valves.
• Drug addicts show a predilection for tricuspid valve involvement by S. aureus, often with a better prognosis than non-addicts.
• Limited clinical trials exist for antibiotic regimens in staphylococcal endocarditis, a potentially devastating infection.

Purpose of the Study:

• To review current understanding and treatment strategies for staphylococcal endocarditis.
• To highlight differences in presentation and prognosis between drug addicts and non-addicts.
• To discuss antibiotic choices, combination therapy, and treatment duration.

Main Methods:

• Review of existing literature and clinical observations regarding staphylococcal endocarditis.
• Analysis of treatment outcomes based on causative staphylococcal species and patient population (drug addicts vs. non-addicts).
• Evaluation of antibiotic efficacy, including penicillin, flucloxacillin, vancomycin, and rifampicin.

Main Results:

• S. aureus commonly affects native and prosthetic valves, particularly the tricuspid valve in drug addicts.
• S. epidermidis primarily targets prosthetic valves.
• Most S. aureus strains are penicillin-resistant but flucloxacillin-sensitive; vancomycin is used for penicillin-allergic or resistant cases. Combination therapy's impact on morbidity/mortality is unproven.
• Non-addicts face higher mortality and may require emergency valve replacement.

Conclusions:

• Staphylococcal endocarditis requires tailored antibiotic therapy based on susceptibility and patient factors.
• Treatment duration is typically at least 4 weeks, potentially shorter in drug addicts.
• Further clinical trials are needed to optimize antibiotic regimens and determine the ideal treatment length.